99 related articles for article (PubMed ID: 12353319)
1. CML after treatment for lymphoid malignancy: Therapy-related CML or coincidence?
Bolaños-Meade J; Sarkodee-Adoo C; Khanwani SL
Am J Hematol; 2002 Oct; 71(2):139. PubMed ID: 12353319
[No Abstract] [Full Text] [Related]
2. Chronic myeloid leukemia in a patient with colon adenocarcinoma.
Gokel Y; Paydas S
Haematologia (Budap); 2002; 32(4):501-3. PubMed ID: 12803125
[TBL] [Abstract][Full Text] [Related]
3. Chronic myeloid leukemia after treatment of lymphoid malignancies: response to imatinib mesylate and favorable outcomes in three patients.
Ramanarayanan J; Dunford LM; Baer MR; Sait SN; Lawrence W; McCarthy PL
Leuk Res; 2006 Jun; 30(6):701-5. PubMed ID: 16330096
[TBL] [Abstract][Full Text] [Related]
4. [Chronic myelogenous leukemia following therapy for pineal germinoma].
Noda M; Shoda T; Takimoto Y; Okita H
Rinsho Ketsueki; 2004 Jan; 45(1):72-4. PubMed ID: 14999938
[TBL] [Abstract][Full Text] [Related]
5. [A case of chronic myeloid leukemia following TS-1 therapy for advanced gastric cancer].
Higuchi M; Nishinaka H; Yamano Y
Gan To Kagaku Ryoho; 2006 Dec; 33(13):2049-52. PubMed ID: 17197751
[TBL] [Abstract][Full Text] [Related]
6. Therapy-related acute myeloid leukemia after single-agent treatment with fludarabine for chronic lymphocytic leukemia.
Lam CC; Ma ES; Kwong YL
Am J Hematol; 2005 Aug; 79(4):288-90. PubMed ID: 16044456
[TBL] [Abstract][Full Text] [Related]
7. Favorable early response of secondary chronic myeloid leukemia to imatinib.
Waldman D; Weintraub M; Freeman A; Neumann Y; Rechavi G; Toren A
Am J Hematol; 2004 Apr; 75(4):217-9. PubMed ID: 15054813
[TBL] [Abstract][Full Text] [Related]
8. Risk factors for development of a second lymphoid malignancy in patients with chronic lymphocytic leukaemia.
Maddocks-Christianson K; Slager SL; Zent CS; Reinalda M; Call TG; Habermann TM; Bowen DA; Hoyer JD; Schwager S; Jelinek DF; Kay NE; Shanafelt TD
Br J Haematol; 2007 Nov; 139(3):398-404. PubMed ID: 17910629
[TBL] [Abstract][Full Text] [Related]
9. Is there an entity of chemically induced BCR-ABL-positive chronic myelogenous leukemia?
Lichtman MA
Oncologist; 2008 Jun; 13(6):645-54. PubMed ID: 18586919
[TBL] [Abstract][Full Text] [Related]
10. The effect of cyclosporin A used alone and in combination with either 2-chlorodeoxyadenosine or fludarabine on normal and chronic myelogenous leukemia progenitors in vitro.
Korycka A; Robak T
Arch Immunol Ther Exp (Warsz); 2003; 51(1):61-7. PubMed ID: 12691305
[TBL] [Abstract][Full Text] [Related]
11. Therapy-related chronic myeloid leukemia: an epidemiological, clinical and pathogenetic appraisal.
Aguiar RC
Leuk Lymphoma; 1998 Mar; 29(1-2):17-26. PubMed ID: 9638972
[TBL] [Abstract][Full Text] [Related]
12. Blastic mantle cell lymphoma developing concurrently in a patient with chronic myelogenous leukemia and a review of the literature.
Rodler E; Welborn J; Hatcher S; Unger K; Larkin E; Gumerlock PH; Wun T; Richman C
Am J Hematol; 2004 Apr; 75(4):231-8. PubMed ID: 15054816
[TBL] [Abstract][Full Text] [Related]
13. Philadelphia chromosome-positive acute lymphoblastic leukemia after therapy for Langerhans cell histiocytosis.
Tatsumi T; Shimazaki C; Araki SI; Sudo Y; Yamagata N; Ashihara E; Goto H; Inaba T; Fujita N; Nakagawa M; Misawa SI; Imashuku S
Am J Hematol; 1997 Jan; 54(1):88. PubMed ID: 8980271
[No Abstract] [Full Text] [Related]
14. Comment to: Secondary malignancies after treatment for indolent non-Hodgkin's lymphoma: a 16-year follow-up study. Haematologica 2008; 93:398-403.
van der Spek E; van der Griend R
Haematologica; 2008 Jul; 93(7):e57; author reply e58. PubMed ID: 18591617
[No Abstract] [Full Text] [Related]
15. Hematological and molecular response evaluation of CML patients on imatinib.
Gupta A; Prasad K
J Assoc Physicians India; 2007 Feb; 55():109-13. PubMed ID: 17571739
[TBL] [Abstract][Full Text] [Related]
16. Effects of age on prognosis with imatinib mesylate therapy for patients with Philadelphia chromosome-positive chronic myelogenous leukemia.
Cortes J; Talpaz M; O'Brien S; Giles F; Beth Rios M; Shan J; Faderl S; Garcia-Manero G; Ferrajoli A; Wierda W; Kantarjian H
Cancer; 2003 Sep; 98(6):1105-13. PubMed ID: 12973833
[TBL] [Abstract][Full Text] [Related]
17. Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate.
Cortes J; Talpaz M; O'Brien S; Jones D; Luthra R; Shan J; Giles F; Faderl S; Verstovsek S; Garcia-Manero G; Rios MB; Kantarjian H
Clin Cancer Res; 2005 May; 11(9):3425-32. PubMed ID: 15867244
[TBL] [Abstract][Full Text] [Related]
18. Fludarabine-related myeloid leukemia.
Astrow AB
J Clin Oncol; 2003 Oct; 21(19):3709; author reply 3709-10. PubMed ID: 14512411
[No Abstract] [Full Text] [Related]
19. Combination of liposomal daunorubicin (DaunoXome), fludarabine, and cytarabine (FLAD) in patients with poor-risk acute leukemia.
Clavio M; Venturino C; Pierri I; Garrone A; Miglino M; Canepa L; Balleari E; Balocco M; Michelis GL; Ballerini F; Gobbi M
Ann Hematol; 2004 Nov; 83(11):696-703. PubMed ID: 15322763
[TBL] [Abstract][Full Text] [Related]
20. First and second line imatinib treatment in chronic myelogenous leukemia patients expressing rare e1a2 or e19a2 BCR-ABL transcripts.
Andrikovics H; Nahajevszky S; Szilvási A; Bors A; Adám E; Kozma A; Kajtár B; Barta A; Poros A; Tordai A
Hematol Oncol; 2007 Sep; 25(3):143-7. PubMed ID: 17530620
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
